Phenoxybenzamine is a medication used in the management and treatment of paroxysmal hypertension and sweating resulting from pheochromocytoma. It is in the nonselective, irreversible antagonist of the alpha-adrenergic receptors class of drugs. Mechanistically it is an alkylating agent that forms a reactive aziridinium intermediate that covalently modifies alpha-adrenergic receptor sites, producing long-lasting blockade of both alpha1 and alpha2 receptors; because binding is essentially irreversible the pharmacodynamic effect persists until new receptors are synthesized. Clinically this causes decreased peripheral vascular resistance, orthostatic hypotension and potential reflex tachycardia, and it is used principally for preoperative stabilization of catecholamine-secreting tumors and for control of paroxysmal hypertensive episodes; the drug is orally bioavailable with variable absorption, undergoes hepatic metabolism and renal excretion, and dosing is individualized and titrated to hemodynamic response.
Parent: Chloropyramine / Phenoxybenzamine
Parent: Chloropyramine / Phenoxybenzamine
Parent: Phenoxybenzamine
Parent: Phenoxybenzamine
Parent: Phenoxybenzamine
Pharmaceutical quality control of phenoxybenzamine batches typically targets high assay purity and tight limits for related substances and process impurities; a representative specification framework used by manufacturers is an assay within 98.0 to 102.0 percent of labeled potency, individual unidentified impurity limits commonly set at not more than 0.5 percent w/w, any single identified related compound often limited to 0.2 to 0.5 percent w/w, and a total related compounds limit typically not exceeding 1.0 percent w/w, while genotoxic or mutagenic impurities are controlled to much lower thresholds in accordance with ICH M7, generally below 0.05 percent w/w or per permitted daily exposure guidance. Additional controls include limits for residual solvents in line with ICH Q3C, heavy metals within pharmacopeial limits, and stability-indicating degradation profiling to ensure degradants remain within specification throughout shelf life.
Phenoxybenzamine is primarily used to control paroxysmal hypertension and excessive sweating caused by pheochromocytoma and to stabilize patients preoperatively to prevent catecholamine crises; it may also be used in specific off-label situations requiring sustained alpha blockade where irreversible long-acting antagonism is desirable.
Phenoxybenzamine is a nonselective alpha-adrenergic antagonist that blocks both alpha1 and alpha2 receptors irreversibly, producing long-duration alpha blockade with consequent vasodilation and potential alterations in sympathetic feedback mediated by presynaptic alpha2 receptors.
The principal difference is mechanism and duration: phenoxybenzamine irreversibly alkylates alpha receptors and produces prolonged blockade, while phentolamine is a reversible competitive nonselective alpha antagonist with a rapid onset and short duration useful for acute, short-term management of hypertensive episodes; their clinical uses and hemodynamic profiles differ accordingly.
There is no specific chemical antidote because phenoxybenzamine irreversibly blocks receptors; management of overdose or severe hypotension is supportive with intravenous fluids and vasopressor support, and agents that act via nonadrenergic receptors such as vasopressin are often preferred because catecholamine vasopressors may be less effective until receptor function is restored by new receptor synthesis.
